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Abstract 
 
 A simple and efficient method has been developed for the synthesis of various 
pyrazolo[3,4-d]pyrimidines using microwave irradiation under solvent-free 
conditions. The advantages of applying microwave irradiation compared with the 
classical method were demonstrated. The structures of all the compounds were 
confirmed by the usual techniques and in two cases by X-ray analysis. The 
compounds did not display appreciable ability to inhibit xanthine oxidase activity. 
Screening for antifungal activity showed that some derivatives were active against 
four fungi, with more significant results for Botrytis. 
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Introduction 
The development of simple and eco-friendly synthetic procedures constitutes 
an important goal in organic synthesis. Microwave assisted organic synthesis 
(MAOS) is a fast growing area of research, due to the generally short reaction 
times, high purities and yields of the resulting products when compared to 
conventional methods [1]. 
Microwave irradiation has been used to effect organic reactions such as 
pericyclic [2], cyclization [3], aromatic substitution [4], oxidation, [5] alkylation 
[6], decarboxylation [7], radical reactions [8], condensation [9] and peptide 
synthesis [10]. 
Solvent-free reactions under microwave irradiation are the subject of constant 
development because of its ease of set-up, mild conditions, and increased yields of 
products, cost efficiency and environment friendliness compared to their solution 
counterparts [11]. 
As part of our ongoing research program on heterocyclic compounds which 
may serve as leads for designing novel chemotherapeutic agents, we were 
particularly interested in pyrazolopyrimidines [12]. The pyrazole and pyrimidine 
derivatives have attracted the organic chemists interest due to their biological 
importance. Pyrazolopyrimidines and related fused heterocycles are known to 
exhibit several pharmacological activities such as CNS depressant [13], 
neuroleptic [14], tuberculostatic [15], antibacterial and antifungal [16]. 
Pyrazolo[3,4-d]pyrimidines were also identified as a general class of adenosine 
receptors [17]. Furthermore, their ability to inhibit the activity of xanthine oxidase 
was recently described by our group [18].  
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Thus in search of an innovative and reliable method for the synthesis of 
pyrazolopyrimidines, we decided to synthesise 4-aminopyrazolopyrimidines by 
the Taylor modification of von Niementowski reaction [19] using microwave 
irradiation. The validity of MAOS to build the 4-aminopyrimidine moiety of the 
4-aminoquinazoline nucleus was already established by Seijas et al. under 
solvent-free conditions and potassium tert-butoxide as base [20], which proved to 
be a valuable tool for the preparation of this type of compounds [21-22].  
 
Results and discussion. -1- Chemistry. The preparation of the pyrazolo[3,4-
d]pyrimidines involved the reaction of the respective pyrazoles with aromatic 
nitriles under microwave irradiation in a CEM  Discover monomode oven. Three 
pyrazoles were studied with different substitution in the N-aryl group, these were 
condensed with different nitriles such as benzonitrile, benzyl cyanide ( 
phenylacetonitrile), 3-cyanophenyl nitrile, nicotinonitrile, isonicotinonitrile, 2-
thiophenecarbonitrile and 2-furanecarbonitrile.  
A typical experiment involved mixing the pyrazole the nitrile and Kt-BuO in 
a 1:1.1:0.2 ratio followed by irradiation at 300Watt in an open vessel for 10 
minutes, the reactions were carried out in absence of solvent and yields ranged 
from good to moderate. The improvement regarding the conventional conditions 
was very clear since pyrazolo[3,4-d]pyrimidines, (of the type discussed here, 
Scheme 1) are synthesized by vigorously heating o-aminonitriles with nitriles in a 
sealed tube at elevated temperatures for extended time periods [23]. 
INSERT SCHEME 1 
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For example, when 1-phenyl-5-amino-4-cyanopyrazole was subjected to 
microwaves in the presence of 2-phenylacetonitrile and Kt-BuO, the reaction 
occurred smoothly in 10 minutes giving 1b in 83% yield. Overall yields ranged 
from 40- 85%.  
The formation of the pyrazolo[3,4-d]pyrimidine system was unequivocally 
established after analysis of NMR data of the products (Fig. 1 shows the 
numbering of the atoms). The chemical shifts and multiplicity of the protons were 
in consonance with the expected values, for example, the proton at position 3 of 
all the compounds was found between 8.28 and 8.78 ppm as a sharp singlet. The 
signal for NH2 appears as a broad singlet between 7.37 and 8.22 ppm. For 
compounds 2a-2g and 3a-3g the doublets for the para substituted phenyl ring are 
well separated, for compound 2b, for example, they appear at 8.27 and 7.58 ppm. 
The corresponding signals for the pyrazole precursor of compounds 2 [18] are 
7.79, 6.76, 7.52 and 7.57, for H3, NH2 and the phenyl ring protons, respectively. 
The 13C data confirm also that the expected products were obtained, for example 
C(4) (73.49 for pyrazole) shows a very high chemical shift (159.29-156.60 ppm), 
as it is expected for a C linked to an amino group. Another evidence is the 
disappearance of the cyano absorption band at 2230 cm-1, corresponding to the 
starting material, for all compounds except 1c, 2c and 3c. 
All the new compounds were characterized by spectroscopic methods and 
elemental analysis or high resolution mass spectrometry (see Exper. Part). Other 
techniques, such as HMQC and HMBC were also used. 
INSERT FIG. 1 
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2. X-ray analysis. The structure of compounds 1a and 1b was also confirmed 
by X-ray crystallography, from their crystal data. The crystals, obtained from 
dimethyl sulfoxide, were mounted on glass fibers and diffraction data were 
collected at 100 K with Mo-Kα radiation (k = 0.71073 A˚) with APEX2 v2.1-4 
(Bruker AXS B.V., 2007); structure was solved with program: SIR97 [24]; and 
refinement was carried out with: SHELXL97 [25]. 
In the crystal structure of compound 1a molecules are paired by two hydrogen 
bonds as shown in fig. 2. 
INSERT FIG. 2 
 
In the X-ray from 1b there is a third hydrogen bond involving the pyrazole ring 
from a third molecule (fig. 3). 
INSERT FIG. 3 
Compound 1a; C18H15N5, Mr = 301.350, Monoclinic, group P21/n, a = 
14.3727 (2) Å, b = 7.72200 (10) Å, c = 14.4919 (2) Å, β= 108.8630 (10) Å, V = 
1522.02 (4) Å3, Z = 4, Dx = 1.315 Mg m−3, λ= 0.71073 Å, Mo-Kα radiation, λ = 
0.7107 Å; cell parameters from 9265 reflections, θ= 2.42– 28.21 µ = 0.083 mm−1, 
T = 296 (2) K, Prism colourless 0.26 × 0.25 × 0.12 mm.1 
Compound 1b, 2(C17H13N5), Mr = 574.65, Monoclinic, P21/c, a = 10.1482 (2) 
Å, b = 12.8286 (2) Å, c = 21.5776 (4) Å, β = 102.1050 (10)º, V = 2746.67 (9) Å3, 
                                                 
1
 CCDC 665130 contains the supplementary crystallographic data for 1a. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif.  
 
 7 
Z = 4, λ= 0.71073 Å, Mo-Kα radiation, λ = 0.7107 Å, µ = 0.09 mm-1, T = 100 (2) 
K, Prism yellow 0.52 × 0.35 × 0.16 mm.2 
 
3. Biological activity. 3.1. Effects of compounds on xanthine oxidase. The 
inhibition of xanthine oxidase activity by pyrazolo[3,4-d]pyrimidines (1-3) was 
examined at the maximum concentration of 120 µM. No appreciable activity was 
observed, except for compounds 1e, 2b, and 3e. These pyrazolo[3,4-d]pyrimidines 
were further tested at a wide range of concentrations in order to determine its IC50 
values (Table 1). The results obtained for these compounds revealed a weak 
inhibitory effect. 
INSERT TABLE 1 
 
3.2. Antifungal Activity. The compounds were screened for their antifungal 
activity, against Alternaria sp. isolated from grape vine (nº UTAD 175), Botrytis 
spp. isolated from apple (nº UTAD 158), Septoria nodorum isolated from triticale 
(nº UTAD 35) and Phytophthora cinnamomi isolated from chestnut trees (nº 
UTAD 107 and IMI nº340340).  
Pyrazolopyrimidines 1 exhibited the highest activity against the four fungi but 
mainly for Botrytis; the best results are shown in the Table 2. P cinamomi is only 
highly sensitive to compound 1c (200 ppm) and slightly to moderately sensitive 
for all the other compounds tested. These results could be explained by the 
phylogenetic sense, since P. cinnamomi can no longer be classified as fungi. 
                                                 
2
 CCDC 665129 contains the supplementary crystallographic data for 1b. These data can be 
obtained free of charge from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif. 
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Therefore, it is now included as oomycetes in Chromista kingdom which differ 
from true fungi by their unique molecular systems.  
INSERT TABLE 2 
 
Conclusion 
A total of twenty one pyrazolopyrimidines, eighteen of which new, were 
prepared by a microwave solvent free reaction in moderate to good yields. The 
structures of all the compounds were confirmed by the usual techniques and in 
two cases by X-ray analysis. Considering biological activities no substantial 
ability to inhibit xanthine oxidase was observed. 
All the compounds were also screened for their antifungal activity and 
pyrazolopyrimidines 1 exhibited the highest activity against the four fungi but the 
results were more significant Botrytis.  
 
 
Experimental Part 
General. Petroleum ether (PE) had a b.p. range of 40-60º. Column 
chromatography (CC): silica gel 60 (70-230 mesh; Merck). Melting points (m.p.): 
Gallenkamp apparatus; uncorrected. UV Spectra: Hitachi U-2000 apparatus; λmax 
(log ε) in nm. IR Spectra: Perkin Elmer FTIR-1600; in cm-1. NMR Spectra: Varian 
Unity Plus Spectrometer apparatus; at 300 MHz (1H) and 75.4 MHz (13C) in 
DMSO (unless noted otherwise); δ in ppm rel. to solvent peak or Me4Si, J in Hz. 
NMR Assignments are based on 2-D NMR experiments (HMQC, HMBC). EI and 
HR-EI-MS: VG AutoSpecE mass spectrometer. Elemental analyses: Leco CHNS-
932 apparatus.  
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Column chromatography was performed with mixtures of light petroleum and 
ethyl acetate of increasing polarity, unless other conditions are described.  
Microwave experiments were conducted using a CEM Discover monomode 
oven operating at 2450 MHz monitored by a PC computer and  temperature 
maintained at a constant value by power modulation (0-300 W). Stirring was 
provided by an in situ magnetic stirrer. Reactions were performed in open glass 
vessels (capacity 10 mL). 
Reaction conditions: Power- 300W; Solvent-No; Ramp time- 3 min; Hold 
time- 10 min; Stirring- On; Temperature- 145º C. 
 
Usual Procedure: 
To the pyrazole (0.5 mmol) taken in the special open glass vessel, was added 
the nitrile (0.6 mmol) and potassium tert-butoxide (10 mg, 0.089 mmol). The 
mixture was thoroughly mixed and the tube was then subjected to microwave 
irradiation following the above protocol. The reaction mixture was purified either 
by column chromatography in light petroleum/ethyl acetate or by re-
crystallisation from ethanol. 
1,6-Diphenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1a). The title compound 
was obtained as an off-white solid (85%). M.p. 224-226º (lit. 71%, m.p. 224-225º 
[23]). IR (Nujol): 3381, 2726, 2671, 1648, 1588, 1566, 1168, 971, 774, 722. 1H-
NMR: 8.47-8.40 (m, H-C(2”) and H-C(6”)); 8.36 (s, H-C(3)); 8.32 (d, J = 9.0, H-
C(2’) and H-C(6’)); 8.08-7.76 (br. s, NH2); 7.59 (t, J = 8.2, H-C(3´) and H-C(5´ 
)); 7.51-7.47 (m, H-C(3’’), H-C(5’’) and H-C(4’’)); 7.35 (t, J = 7.2, H-C(4’)). 13C- 
NMR: 161.95; 158.33; 154.61; 139.26; 138.04; 134.25; 130.51; 129.32 (2C); 
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128.42 (2C); 128.19 (2C); 126.04; 120.51 (2C); 100.37. HR-EI-MS: 287.1171 
(M+, C17H13N5; calc. 287.1172). 
6-Benzyl-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1b). The title 
compound was obtained as an off-white solid (83%). M.p. 220-222º (lit. 57%, 
m.p. 220-222º [23]).  IR (Nujol): 3278, 2781, 2674, 1588, 1566, 1175, 971, 774. 
1H-NMR: 8.28 (s, H-C(3)); 8.20 (dt, J = 7.5 and 1.5, H-C(2’) and H-C(6’)); 7.64-
7.96 (br. s, NH2); 7.51 (t, J = 7.5, H-C(3’) and H-C(5’)); 7.35-7.22 (m, H-C(2’’), 
H-C(3”), H-C(4”), H-C(5”)  and H-C(6’’)); 7.17 (tt, J = 7.2 and 1.5, H-C(4’)); 
4.01 (s, CH2). 13C-NMR: 167.72; 158.39; 154.39; 139.22; 138.99; 134.06; 129.22 
(2C); 129.09 (2C); 128.30 (2C); 126.23; 126.00; 120.44 (2C); 99.82; 45.51 (CH2). 
HR-EI-MS: 300.1249 (M+-1, C18H15N5; calc. 300.1253). 
3’-(4-Amino-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-6-yl)benzonitrile (1c). 
Compound 1c was obtained as a yellow solid (41%). M.p. 238-239º. IR (Nujol): 
3182, 2737, 2242, 1662, 1578, 1561, 1314, 1167, 987, 819, 792, 719. 1H- NMR: 
8.66-8.73 (m, H-C(4”) and H-C(2”)); 8.38 (s, H-C(3)); 8.26 (dd, J = 8.7 and 1.2, 
H-C(2’) and H-C(6’)); 8.05-8.22, (br. s, NH2); 7.96 (dt, J = 7.5 and 1.5, H-C(6”)); 
7.73 (t, J = 8.8, H-C(5”)); 7.59 (t, J = 8.0, H-C(3’) and H-C(5’)); 7.36 (tt, J = 7.5 
and 1.2, H-C(4´)). 13C-NMR: 159.82; 158.37; 154.24; 139.17; 139.02; 134.30; 
133.80; 132.55; 131.48; 129.92; 129.35 (2C); 126.23; 120.74 (2C); 118.82 (CN); 
111.63; 100.65. HR-EI-MS: 312.1123 (M+, C18H12N6; calc. 312.1122). 
1-Phenyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1d). The title 
compound was obtained as a light yellow solid (64%). M.p. 239-241º (lit. 71%,   
m.p. 239-240º [23]). IR (Nujol): 3174, 2726, 2672, 1649, 1586, 1063, 972, 772.  
1H-NMR: 9.54 (d, J = 2.1, H-C(2’’)); 8.67-8.64 (m, H-C(4”) and H-C(6”)); 8.39 
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(s, H-C(3)); 8.30 (dd, J = 8.7 and 1.2, H-C(2’) and H-C(6’)); 8.16 and 7.96 (2 br. 
s, NH2); 7.52-7.64 (m, H-C(3´), H-C(4´), H-C(5´)); 7.36 (t, J = 7.5, H-C(5”)). 13C-
NMR: 160.21; 158.38; 154.21; 151.06; 149.40; 139.08; 135.42; 134.30; 133.40; 
129.33 (2C); 126.15; 123.63; 120.57 (2C); 100.53. HR-EI-MS: 288.1123 (M+, 
C16H12N6; calc. 288.1122). 
1-Phenyl-6-(pyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1e). A light 
yellow solid was obtained (70%). M.p. 289-290º. IR (Nujol): 3187, 2735, 2678, 
1654, 1568, 978, 785. 1H-NMR: 8.74 (br. d, J = 6.0, H-C(2’’) and H-C(6’’)); 8.41 
(s, H-C(3)); 8.29 (m, H-C(2’) and H-C(6’)); 8.27 (m, H-C(3’)’ and H-C(5’’)); 8.18 
and 8.01 (2 br. s, NH2); 7.60 (tt, J = 7.5 and 2.0, H-C(3’) and H-C(5’)); 7.36 (tt, J 
= 7.2 and 1.2, H-C(4’)). 13C-NMR: 159.89; 158.42; 154.13; 150.20 (2 C); 145.23; 
138.98; 134.25; 129.29 (2C); 126.17; 121.96 (2C); 120.59 (2C); 100.89. HR-EI-
MS: 288.1123 (M+, C16H12N6; calc. 288.1122). Anal.calc. for C16H12N6: C 66.65, 
H 4.2, N 29.15; found: C 66.7, H 4.,; N 29.0.  
6-(Thiophen-2-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1f). The 
title compound was obtained as a off-white solid (47%). M.p. 178-180º.  IR 
(Nujol): 3184, 2726, 1646, 1586, 1225, 1212, 970, 823, 786, 720, 703. 1H- NMR: 
8.33 (s, H-C(3)); 7.80-8.06 (br. s, NH2); 8.30 (dd, J = 7.5 and 1.5, H-C(2’) and H-
C(6’)); 7.93 (dd, J = 3.6 and 1.2, H-C(3’’)); 7.69 (dd, J = 5.3 and 1.5, H-C(5’’)); 
7.57 (t, J = 7.5, H-C(3’) and H-C(5’)); 7.34 (t, J = 7.5, H-C(4’); 7.18 (dd, J = 5.0 
and 3.9 Hz, H-C(4’’)). 13C-NMR: 158.59; 158.14; 154.03; 143.98; 139.16; 
134.31; 130.09; 129.20 (2C); 128.46; 128.18; 125.93; 120.23 (2C), 100.11. HR-
EI-MS: 293.0735 (M+, C15H11N5S; calc. 293.0736). Anal. calc. for C15H11N5 S: C 
61.42; H 3.7; N 23.87; S 10.93; found: C 61.42; H 3.69; N 23.78; S 11.13. 
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6-(Furan-2-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (1g). A light 
brown solid was obtained (40%). M.p. 204-206º. IR (Nujol): 3278, 2781, 2674, 
1588, 1566, 1175, 965, 889, 823, 780. 1H-NMR: 8.92 (d, J = 7.8, H-C(2’) and H-
C(6’)); 8.78 (s, H-C(3)); 8.25-8.20 (m, H-C(5’’)); 8.03 (t, J = 8.0, H-C(3’) and H-
C(5’)); 7.87 (br. s, NH2); 8.40-7.76 (m, H-C(4’) and H-C(3’’)); 7.10 (dd, J = 3.6 
and 1.5, H-C(4’’)). 13C-NMR: 159.41; 156.43; 155.45; 154.09, 145.48; 140.67; 
134.22; 129.74 (2C); 126.60; 121.34 (2C); 113.81; 112.68; 101.31. HR-EI-MS: 
277.0964 (M+, C15H11N5O; calc. 277.0965).  
1-(4-Chlorophenyl)-6-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (2a). 
Light yellow crystals were obtained (74%). M.p. 231-233º. IR (Nujoll): 3378, 
2753, 2693, 1662, 1588, 1536, 1181, 972, 774, 724. 1H-NMR: 8.46-8.41 (m, H-
C(2’’) and H-C(6’’)); 8.38 (d, J = 8.7, H-C(2’) and H-C(6’)); 8.30 (s, H-C(3)); 
8.10-7.84 (br. s, NH2); 7.65 (d, J = 9.0, H-C(3)’ and H-C(5’)); 7.54-7.47 (m, H-
C(3’’), H-C(4”) and H-C(5’’)). 13C-NMR: 161.99; 158.23; 154.65; 138.02; 
137.84; 134.56; 130.47; 129.88; 128.30 (2C); 129.20 (2C); 128.14 (2C); 121.76 
(2C); 100.33. HR-EI-MS: 321.0781 (M+, C17H1235ClN5; calc. 321.0769). Anal. 
calc. for C17H12Cl N5: C 63.46; H 3.76; N 21.77; Cl 11.02; found: C 63.49; H 
3.72; N 21.86; Cl 11.04. 
6-Benzyl-1-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (2b). An 
off-white solid was obtained (42%). M.p. 226-228º. IR (Nujol): 3278, 2781, 2674, 
1588, 1566, 1175, 971, 774. 1H-NMR: 8.29 (s, H-C(3)); 8.27 (d, J = 7.0, H-C(2’) 
and H-C(6’)); 7.85 (br. s, NH2); 7.58 (d, J = 7.0, H-C(3’) and H-C(5’)); 7.28 (t, J 
= 7.5, H-C(3’’) and H-C(5’’)); 7.14- 7.38 (m, H-C(2’’) and H-C(6’’)); 7.18 (t, J = 
7.2, H-C(4’’)); 4.01 (s, CH2Ar). 13C-NMR: 167.80; 158.32; 154.44; 138.83; 
 13 
138.04; 134.41; 129.81; 129.11 (2C); 129.03 (2C); 128.22 (2C); 126.17; 121.61 
(2C); 99.80; 45.42 (CH2). HR-EI-MS: 335.0944 (M+, C18H1435ClN5; calc. 
335.0938).  
3-(4-Amino-1-(4-chlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)benzonitrile 
(2c). The title compound was obtained as a yellow solid (51%). M.p. 243-245º. IR 
(Nujol): 3157, 2716, 2274, 1662, 1589, 1559, 1311, 1172, 978, 817, 784, 726. 1H-
NMR: 8.66-8.64 (m, H-C(2’’) and H-C(4’’)); 8.39 (s, H-C(3)); 8.32 (dd, J = 7.2 
and 2.1, H-C(2’) and H-C(6’)); 8.20 and  8.00 (2 br. s, NH2);  7.95 (dt, J = 7.8 and 
1.5, H-C(6’’)); 7.73 (t, J = 7.8, H-C(5’’)); 7.65 (dd, J = 6.9 and 2.1,  H-C(3’) and 
H-C(5’)). 13C-NMR: 159.90; 158.30; 154.30; 139.00; 137.80; 134.63; 133.84; 
132.55; 131.43; 130.14; 129.83; 129.27 (2C); 122.03 (2C); 118.72(CN); 111.60; 
100.65. HR-EI-MS: 346.0734 (M+, C18H11N635Cl; calc. 346.0739).  
1-(4-Chlorophenyl)-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(2d). An off-white solid was obtained (67%). M.p. 241-243º. IR (Nujol): 3187, 
2735, 2678, 1654, 1568, 978, 785. 1H-NMR: 9.5 (br. s, H-C(2’’)); 8.65-8.73 (m, 
H-C(4’’) and H-C(6’’)); 8.39 (s, H-C(3)); 8.36 (d, J = 9.0, H-C(2’) and H-C(6’)); 
8.16 and 8.00 (2 br. s, NH2); 7.65 (d, J = 9.0, H-C(3’) and H-C(5’)); 7.50-7.58 (m, 
H-C(5’’)). 13C-NMR: 160.37; 158.38; 154.35; 151.14; 137.93; 135.50; 135.42; 
134.70; 133.28; 130.12; 129.33 (2C); 123.62; 121.97 (2C); 100.61. HR-EI-MS: 
322.0734 (M+, C16H11N635Cl; calc. 322.0734). Anal. calc. for C16H11N6 Cl: C 
59.54; H 3.44; N 26.04; Cl 10.98; found: C 59.56; H 3.44; N 26.14; Cl 10.92. 
1-(4-Chlorophenyl)-6-(pyridin-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(2e). The compound was obtained as yellow crystals (69%). M.p. 267-269º. IR 
(Nujol): 3174, 2726, 2672, 1649, 1586, 1063, 972, 772. 1H-NMR: 8.74 (d, J = 6.3, 
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H-C(2’’) and H-C(6’’)); 8.42 (s,  H-C(3)); 8.34 (d, J = 9.0, H-C(2’) and H-C(6’)); 
8.28 (d, J = 6.3, H-C(3’’) and H-C(5’’)); 8.20 and 8.00 (2 br. s, NH2); 7.66 (d, J = 
6.5, H-C(3’) and H-C(5’)). 13C-NMR: 160.06; 158.43; 157.42; 150.23 (2C); 
145.10; 137.82; 134.67; 130.20; 129.32 (2C); 122.03 (4C); 100.96. HR-EI-MS: 
322.0745 (M+, C16H11N635Cl; calc. 322.0734).  
1-(4-Chlorophenyl)-6-(thiophen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(2f). An off-white solid was isolated (40%). M.p. 190-192º. IR (Nujol): 3176, 
2732, 1654, 1586, 1233, 1212, 970, 853, 786, 755, 712. 1H-NMR: 8.34 (d, J = 9.0, 
H-C(2’) and H-C(6’)); 8.34 (s, H-C(3)); 7.94 (dd, J = 3.9 and 1.2, H-C(3’’)); 7.70 
(dd, J = 5.1 and 1.2, H-C(5’’)); 7.62 (d, J = 9.3, H-C(3’) and H-C(5’)); 7.90-8.04 
(br. s, NH2); 7.18 (dd, J = 5.1 and 3.9, H-C(4’’)). 13C-NMR: 158.87; 158.27; 
154.29; 143.88; 138.10; 134.84; 130.38; 130.09; 129.35 (2C); 128.84; 128.39; 
121.82 (2C); 100.25. HR-EI-MS: 327.0345 (M+, C15H1035ClN5S; calc. 327.0353).  
1-(4-Chlorophenyl)-6-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (2g).  
An off-white solid was isolated (45%). M.p. 206-208º. IR (Nujol): 3269, 2781, 
2685, 1587, 1586, 1175, 957, 889, 831, 772. 1H-NMR: 8.53 (d, J = 9.3, H-C(2’) 
and H-C(6’)); 8.35 (s, H-C(3)); 8.0 (br. s, NH2); 7.70-7.90 (m, H-C(4’’)); 7.62 (d, 
J = 9.3, H-C(3’) and H-C(5’)); 7.34 (dd, J = 3.3 and 0.9, H-C(3’’)); 6.66 (dd, J = 
3.3 and 1.8, H-C(5’’)). 13C-NMR: 159.41; 156.60; 153.99; 145.60; 141.80; 
139.48; 134.65; 131.32; 129.80 (2C); 122.58 (2C); 114.01; 112.74; 101.34. HR-
EI-MS: 311.0574 (M+, C15H1035ClN5O; calc. 311.0570).  
1-(4-Bromophenyl)-6-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3a). Light 
yellow crystals were obtained (84%). M.p. 238-239º. IR (Nujol): 3378, 2753, 
2693, 1662, 1588, 1536, 1181, 972, 774, 724. 1H-NMR: 8.47-8.39 (m, H-C(2’)’ 
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and H-C(6’’)); 8.38 (s, H-C(3)); 8.31 (d, J = 9.0, H-C(2’) and H-C(6’)); 8.12-7.80 
(br. s, 2H, NH2); 7.78 (d, J = 9.0, H-C(3’) and H-C(5’)); 7.54-7.47 (m, H-C(3’’), 
H-C(4’’) and H-C(5’’)). 13C-NMR: 162.10; 158.31; 154.75; 138.49; 137.87; 
134.70; 132.23 (2C); 130.61; 128.43 (2C); 128.24 (2C); 122.23 (2C); 118.26; 
100.42. HR-EI-MS: 365.0263 (M+, C17H1279BrN5; calc. 365.0276).  
6-Benzyl-1-(4-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3b). 
Colourless needles were obtained (48%). M.p. 225-227º. IR (Nujol): 3282, 2787, 
2669, 1588, 1578, 1183, 989, 778. 1H-NMR: 8.33 (s, H-C(3)), 8.22 (d, J = 8.7, H-
C(2’) and H-C(6’ )); 7.95-7.74 (br. s, NH2); 7.71 (d, J = 8.7,  H-C(3’) and H-
C(5’)); 7.36-7.23 (m, H-C(2’’), H-C(3’’), H-C(5’’), H-C(6’’)); 7.18 (tt, J = 6.9 
and 1.2, H-C(4’’)); 4.02 (s, CH2Ar). 13C-NMR: 167.79; 158.32; 154.46; 138.81; 
138.46; 134.53; 132.00 (2C); 129.02 (2C); 128.20 (2C); 126.15; 121.90 (2C); 
118.03; 99.82; 45.41. HR-EI-MS: 379.0447 (M+, C18H1179BrN5; calc. 379.0433). 
Anal. calc. for C18H11 Br N5 : C 55.75; H 3.3; N 19.18; Br, 10.98; found: C 55.76; 
H 3.32; N 19.21; Br 11.01. 
3-(4-Amino-1-(4-bromophenyl)-1H-pyrazolo[3,4-d]pyrimidin-6-yl)benzonitrile 
(3c). Light yellow solid (54%). M.p. 245-246º. IR (Nujol): 3185, 2726, 2233, 
1659, 1589, 1561, 1305, 1169, 982, 817, 784, 722. 1H-NMR: 8.72-8.66 (m, H-
C(2’’) and H-C(4’’)); 8.38 (s, H-C(3)); 8.26 (d, J = 8.7, H-C(2’) and H-C(6’)); 
8.22-8.13 (br. s, NH2); 7.95 (dt, J = 7.5 and 1.2, H-C(6’’)); 7.76 (d, J = 8.7, H-
C(3’) and H-C(5’)); 7.71 (t, J = 8.1, H-C(5’’)). 13C-NMR: 159.93; 158.33; 154.34; 
139.00; 138.25; 134.69; 133.88; 132.60; 132.21 (2C); 131.47; 129.87; 122.37 
(2C); 118.77; 118.44 (CN); 111.63; 100.71. HR-EI-MS: 390.0229 (M+, 
C18H1179BrN6; calc. 390.0231).  
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1-(4-Bromophenyl)-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(3d). The titled compound was obtained as yellow crystals (80%). M.p. 243-245º. 
IR (Nujol): 3168, 2757, 2675, 1653, 1586, 1076, 972, 775. 1H-NMR: 9.56 (d, J = 
2.1, H-C(2’’)); 8.68 (d, J = 7.0, H-C(4’’) and H-C(6”)); 8.41 (s, H-C(3)); 8.31 (d, 
J = 9.0, H-C(3’) and H-C(5´)); 8.02 and 8.17 (2 br. s, NH2); 7.79 (d, J = 9.0, H-
C(2’) and H-C(6’)); 7.58-7.52 (m, H-C(5’’)). 13C-NMR: 160.34; 158.33; 154.33; 
151.12; 149.41; 138.30; 135.43; 134.70; 133.22; 132.21 (2C); 123.56; 122.23 
(2C); 118.32; 100.60. HR-EI-MS: 366.0233 (M+, C16H1179BrN6; calc. 366.0229).  
1-(4-Bromophenyl)-6-(pyridine-4-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(3e). An off-white powder was obtained (79%). M.p. 269-271º. IR (Nujol): 3168, 
2757, 2675, 1653, 1586, 1069, 972, 777. 1H-NMR: 8.74 (d, J = 4.7, H-C(2’’) and 
H-C(6’’)); 8.41 (s, H-C(3); 8.29 (d, J = 8.7, H-C(2’) and H-C(6’)); 8.26 (d, J = 
4.8, H-C(3’’) and H-C(5’’)); 8.22 and 8.04 (2 br. s, NH2); 7.77 (d, J = 8.7, H-
C(3’) and H-C(5’)). 13C-NMR: 160.02; 158.40; 154.26; 150.19 (2C); 145.08; 
138.22; 134.67; 132.18 (2C); 122.27 (2C); 121.99 (2C); 118.42; 118.42. HR-EI-
MS: 366.0230 (M+, C16H1179BrN6; calc. 366.022).  
1-(4-Bromophenyl)-6-(thiophen-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
(3f). The title compound was obtained as a yellow solid (57%). M.p. 192-194º. IR 
(Nujol): 3182, 2731, 1639, 1587, 1225, 1202, 970, 834, 783, 717, 709. 1H-NMR 
(Acetone-d6): 8.47 (d, J = 9.0, H-C(2’) and H-C(6’)); 8.34 (s, H-C(3)); 8.06 (dd, J 
= 3.9 and 1.2, H-C(3’’)); 7.65 (dd, J = 5.1 and 1.2, H-C(5’’)); 7.78 (d, J = 9.0, H-
C(3’) and H-C(5’)); 7.37 (br. s, NH2); 7.20 (dd, J = 5.1 and 3.9, H-C(4’’)). 13C-
NMR (Acetone-d6): 160.10; 159.29; 155.64; 145.16; 139.89; 134.80; 132.81 
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(2C); 130.45; 129.55; 128.69; 122.85 (2C); 119.12; 101.34. HR-EI-MS: 370.9840 
(M C15H1079BrN5S; calc. 370.9845).  
1-(4-Bromophenyl)-6-(furan-2-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (3g). 
A dark brown solid was obtained (45%). M.p. 206-208º. IR (Nujol): 3282, 2787, 
2674, 1582, 1568, 1169, 959, 891, 823, 776. 1H-NMR: 8.35 (s, H-C(3)); 8.28 (d, J 
= 9.3, H-C(2’) and H-C(6’)); 8.10-7.91 (br. s, NH2); 7.90-7.87 (m, H-C(5’’)); 7.75 
(d, J = 9.0, H-C(3’) and H-C(5’)); 7.26 (dd, J = 3.3 and 0.9, H-C(3’’)); 6.67 (dd, J 
= 3.3 and 1.5, H-C(4’’)). 13C-NMR: 158.23; 155.25; 154.16; 152.40; 145.20; 
138.39; 134.65; 132.07 (2C); 122.00 (2C); 118.15; 113.21; 112.18; 100.17. HR-
EI-MS: 355.0062 (M+, C15H1079BrN5O; calc. 355.00687).  
 
Biological Assays.  
Xanthine Oxidase Assay. The reaction mixture containing 50 mM potassium 
dihydrogen phosphate buffer, pH 7.4, xanthine oxidase (0.066 U/mL), and a 
solution of test compounds in DMSO was incubated at room temperature, during 
15 minutes. The reaction was started by addition of xanthine (100 µM) in the 
presence of EDTA (1 mM), and uric acid formation was followed by measure of 
absorbance at 295 nm during 2 minutes. Each study corresponds to three 
experiments, performed in triplicate. 
Final concentrations of DMSO (1%) did not interfere with enzyme activity. 
Allopurinol was used as positive control. 
 
Antifungal assays. The compounds, resuspended in DMSO, were screened for 
their antifungal activity, against Alternaria sp. isolated from grape vine (nº UTAD 
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175), Botrytis spp. isolated from apple (nº UTAD 158), Septoria nodorum isolated 
from triticale (nº UTAD 35) and Phytophthora cinnamomi isolated from chestnut 
trees (nº UTAD 107 and IMI nº340340), based on the method of Jasso de 
Rodríguez and co-workers [26]. All isolates were transferred from UTAD stock 
cultures to establish fresh PDA agar cultures in Petri dishes. The test plates were 
incubated at 25ºC after placing a 8 mm agar disc containing the mycelium of 
fungi. When the mycelium of fungi reached the edges of the control plate (with 
DMSO only), the antifungal index was calculated as follows: 
Antifungal index (%) = (1-Da/Db) x 100 
Where Da is the diameter of the growth zone in the test plates and Db is the 
diameter of growth zone in the control plate. Each experiment was performed 
three times, and the data were averaged. 
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Table 1. Inhibitory effects on xanthine oxidase 
Compound IC50 
1e  106,6 ± 6,2 
2b  76,6 ± 2,0 
3e  78,1 ± 6,6 
Results are expressed as means ± SEM of 3 independent observations performed 
in triplicate. Allopurinol was used as positive control (% Inhibition (100 µM) = 96.3 ± 
0.3, IC50 =24.4 ± 0.5 µM) 
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Table 2. Antifungal activity data  
(% inhibition) 
Alternaria Botrytis S. nodorum P. cinnamomi 
Compound 
 
100ppm 200ppm 100ppm 200ppm 100ppm 200ppm 100ppm 200ppm 
1a 35.0 37.0 52.0 76.0     
1b 57.5 64.9 40.0 66.0 31.0 69.0   
1c 42.5 48.6 60.0 78.0 33.3 52.4 63.6 75.0 
1f 57.5 64.9 72.0 78.0 38.1 54.8   
1g     14.3 50.0   
2a 23.0 43.0    14.0  21.0 
2b 22.5 43.2 16.0 60.0     
2e       31.8 56.8 
2f   34.0 60.0     
2g   50.0 46.0     
3d   34.0 66.0     
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 + R'CN
Microwave
N
N
N
N
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R'
NH2
1-3
K t-BuO
 
R = 1) C6H5, 2) p-Cl C6H4, 3) p-Br C6H4 
R’ = a) phenyl, b) benzyl, c) 3-cyanophenyl, d) 3-pyridyl, e) 4-pyridyl, f) 2-
thiophenyl, g) 2-furanyl. 
Scheme 1. Synthesis of pyrazolo[3,4-d]pyrimidines 
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Fig. 1. Numbering of the atoms of compound structures  1-3 
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Fig. 2. X-Ray structure of compound 1a 
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Fig. 3. X-Ray structure of compound 1b 
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Graphical illustration 
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